Expon Capital — 2025 Investments
8 investments dated 2025 · listed companies and verified rows first · show all
Exobiosphere is building a standardized space-based high-throughput testing platform that lets pharma and biotech partners run automated experiments in orbit, using microgravity combined with lab automation and bioinformatics to create more physiologically relevant 3D biology models.
BiotechDeep TechSpace Tech
Kyle Acierno(Co-Founder & Chief Executive Officer)inBruno Santos(Co-Founder & Director of R&D)inOlivia Borgue(Co-Founder & Director of Engineering)in
Co-investorsExpansion Ventures
A company developing in vitro testing methods to assess respiratory sensitization for regulatory compliance in chemical and pharmaceutical industries.
BiotechDeep TechHealthtechMedical Devices
Marketleap manages selling on Amazon EU and UK for brands, handling VAT filing, PPC advertising across markets, localized product pages, and import/export logistics.
AI & Machine LearningE-commerceRetail TechNew York City, US
Mekki Mouaddeb(Founder)in
Co-investorsKima VenturesMotier VenturesSmedvig Ventures
Sympower operates a platform providing demand response and energy flexibility services that help balance national electricity grids across European markets.
AI & Machine LearningCleantechClimate TechEnergyEnterprise Software
Simon Bushell(CEO and founder)inGeorg Rute(Founder)
Co-investorsACTIVATE CAPITAL PARTNERSKickstart InnovationRockstartStartGreen CapitalACTivate CapitalKoolen and Partners+1 more
A company that builds interactive video experience (iVX) solutions designed to engage audiences and deliver measurable results for brands and agencies.
AdTechHealthtechMarketing TechMedia & EntertainmentSaaSTurku, FI
Matias Mäenpää(Founder)in
Co-investorsSuperhero CapitalVolta Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
ClimateCampMAIC Hospitality Solutions
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.



















